Browsing Tag
Apriso
1 post
Alembic Pharmaceuticals secures FDA final approval for generic mesalamine extended-release capsules for ulcerative colitis remission
Alembic Pharmaceuticals gains US FDA approval for its generic mesalamine extended-release capsules, targeting the $133M ulcerative colitis market.
November 2, 2022